ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,812Medicare Part D Prescriptions Filled, Including Refills

Rank: 16 out of 392

$723K Total Retail Price of All Prescriptions

Rank: 3 out of 392

345 Patients Receiving at Least One Drug in Part D
65%Patients 65 Years and Older
67% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New Hampshire
Lower avg

Schedule Two
Controlled Substances

19% of this provider’s 345 patients filled at least one prescription for a schedule two drug, compared to an average of 8%.

Schedule Three
Controlled Substances

8% of this provider’s 345 patients filled at least one prescription for a schedule three drug, compared to an average of 6%.

Risky Drugs to Seniors

0% of this provider’s 5,787 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$93 was the average price of a prescription from this provider, compared to $62 among peers.

Prescriptions per Patient

23 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New Hampshire
LISINOPRIL 332 274 1 1
SIMVASTATIN 265 236 2 2
FUROSEMIDE 245 215 3 6
METOPROLOL TARTRATE 206 195 4 8
OMEPRAZOLE 184 122 5 4
METOPROLOL SUCCINATE 152 120 6 13
LEVOTHYROXINE SODIUM 149 132 7 3
METFORMIN HCL 138 120 8 9
ADVAIR DISKUS 134 95 9 32
AMLODIPINE BESYLATE 128 107 10 5
WARFARIN SODIUM 123 103 11 12
MORPHINE SULFATE ER 111 36 S2 12 71
HYDROCHLOROTHIAZIDE 102 84 13 7
TAMSULOSIN HCL 98 83 14 37
SERTRALINE HCL 96 72 15 19
LANTUS 95 94 16 41
FENTANYL 95 54 S2 16 56
ATORVASTATIN CALCIUM 88 60 18 10
NEXIUM 85 39 19 28
GABAPENTIN 82 51 20 18
OXYCODONE-ACETAMINOPHEN 82 26 S2 20 33
LOVASTATIN 82 75 20 23
OXYCODONE HCL 81 12 S2 23 16
FLUOXETINE HCL 76 44 24 44
IPRATROPIUM-ALBUTEROL 75 75 25 86
CLOPIDOGREL 75 59 25 70
FINASTERIDE 75 66 25 84
HYDROCODONE-ACETAMINOPHEN 70 32 S3 28 14
RISPERIDONE 68 63 29 59
QUETIAPINE FUMARATE 65 61 30 47
PROPRANOLOL HCL 64 21 31 99
PREDNISONE 63 57 32 39
SULFAMETHOXAZOLE-TRIMETHOPRIM 61 51 33 136
PROAIR HFA 60 42 34 36
MIRTAZAPINE 60 60 34 35
TRAMADOL HCL 57 42 36 25
KLOR-CON M20 55 39 37 63
POTASSIUM CHLORIDE 55 53 37 30
LANTUS SOLOSTAR 54 45 39 88
PLAVIX 51 48 40 96
ATENOLOL 51 48 40 11
LOSARTAN POTASSIUM 51 46 40 20
INSULIN SYRINGE 50 49 43 98
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.